Edition:
India

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

165.10USD
1:30am IST
Change (% chg)

$-2.02 (-1.21%)
Prev Close
$167.12
Open
$165.58
Day's High
$165.92
Day's Low
$160.21
Volume
112,277
Avg. Vol
123,898
52-wk High
$220.09
52-wk Low
$41.74

Select another date:

Thu, May 10 2018

BRIEF-Beigene Reports Q1 Net Loss per ADS $2.03

* REVENUES FOR THREE MONTHS ENDED MARCH 31, 2018 WERE $32.54 MILLION, COMPARED TO NIL IN SAME PERIOD IN 2017

BRIEF-BeiGene Says CEO John V. Oyler's 2017 Total Compensation Was $10.3 Million

* BEIGENE LTD SAYS CEO JOHN V. OYLER'S 2017 TOTAL COMPENSATION WAS $10.3 MILLION – SEC FILING Source : https://bit.ly/2r6wtIy Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-BeiGene Appoints J. Samuel Su To Its Board Of Directors

* BEIGENE APPOINTS J. SAMUEL SU TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-BeiGene Qtrly Net Loss Per ADS $2.19

* BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Wellington Management Group Llp Reports 8.39 pct Passive Stake In Beigene Ltd As Of Dec, 29, 2017

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 8.39 PERCENT PASSIVE STAKE IN BEIGENE LTD AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EqL8XD) Further company coverage:

BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China

* BEIGENE ANNOUNCES COMMERCIAL AVAILABILITY OF VIDAZA® (AZACITIDINE FOR INJECTION) IN CHINA

BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage:

Select another date: